Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin-Yoshindo Stake Claim For Play In Japan Biosimilar Enbrel Market

Executive Summary

Lupin and partner Yoshindo have sought marketing authorization for their biosimilar Enbrel in Japan. While not the first biosimilar etanercept in Japan, the NDA is seen opening up multiple opportunities for Lupin as it transitions to “higher complexity” products.

You may also be interested in...



Lupin Paints Better Second Half Riding On Solosec, New US Launch Hopes

Lupin is banking on potential new product introductions and a build-up in sales of Solosec to help drive US growth momentum in the second half of fiscal 2019, but concerns over pipeline weakness persist.

Rough Patch For Lupin, Much Riding On Solosec, Enbrel Biosimilar

An under pressure US business dented Lupin in Q1, with a recovery seen only in the second half of FY19 as new generic products roll out. A ramp-up in on-market products like Solosec in the US and a smooth run to launch for biosimilar Enbrel in Japan and the EU, among other products, could be vital to restore momentum for the Indian firm.

Deal Watch Asia Focus: Merck Partners With Alibaba For Entry To Digital Health In China

China’s Everest licenses global rights to Novartis FGFR4 inhibitor, while Altogen and Lynkogen partner in NASH and metabolic disease.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC123055

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel